Placebo QD

DRUG3 trials

Sponsors

Bristol-Myers Squibb, Galapagos NV, Haihe Biopharma Co., Ltd.

Conditions

Advanced Thymic CarcinomaHepatitis CIdiopathic Pulmonary Fibrosis

Phase 1

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

CompletedNCT01445795

Bristol-Myers SquibbHepatitis C

Start: 2011-09-30End: 2012-05-31Updated: 2016-06-27

Phase 2

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT02738801

Galapagos NVIdiopathic Pulmonary Fibrosis

Start: 2016-03-31End: 2017-05-02Updated: 2020-11-06

Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy

CompletedNCT07824505

Haihe Biopharma Co., Ltd.Advanced Thymic Carcinoma

Start: 2018-08-16End: 2021-09-06Updated: 2026-09-17

Related Papers

An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis

ERJ Open Research2024-01-013 citations

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.

2018-05-20158 citations

Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC.

2018-01-1058 citations